id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1245-0007,FDA,FDA-2012-E-1245,"Letter from U.S. Patent and Trademark Office to Finnegan, Henderson, Farabow, Garrett & Dunner LLP",Other,Letter(s),2014-07-16T04:00:00Z,2014,7,2014-07-16T04:00:00Z,,2014-07-16T18:50:02Z,,0,0,09000064817b2214
FDA-2012-E-1245-0006,FDA,FDA-2012-E-1245,"Determination of Regulatory Review Period for Purposes of Patent
Extension; MENHIBRIX",Notice,General Notice,2014-05-28T04:00:00Z,2014,5,2014-05-28T04:00:00Z,,2014-05-28T14:16:06Z,2014-12294,0,0,0900006481719604
FDA-2012-E-1245-0005,FDA,FDA-2012-E-1245,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-12T04:00:00Z,2014,5,2014-05-12T04:00:00Z,,2014-05-12T17:02:01Z,,0,0,09000064816f1b6b
FDA-2012-E-1245-0004,FDA,FDA-2012-E-1245,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2014-04-08T04:00:00Z,2014,4,2014-04-08T04:00:00Z,,2014-04-09T01:54:58Z,,0,0,09000064816a9f6b